Cargando…
Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months
BACKGROUND AND OBJECTIVE: Sorafenib is recommended for treating advanced hepatocellular carcinoma. However, it is frequently discontinued because of adverse events, which greatly affects its therapeutic effects. Furthermore, because patients treated with sorafenib for a long period can presumably to...
Autores principales: | Katayama, Kazuhiro, Kiyota, Ryosuke, Imai, Toshihiro, Abe, Yutaro, Nawa, Tadatoshi, Wada, Hiroshi, Ohkawa, Kazuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243964/ https://www.ncbi.nlm.nih.gov/pubmed/30483103 http://dx.doi.org/10.1159/000493853 |
Ejemplares similares
-
Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis
por: Katayama, Kazuhiro, et al.
Publicado: (2018) -
Self-expandable metallic stent placement above the papilla without endoscopic sphincterotomy in patients with distal malignant biliary obstruction
por: Takada, Ryoji, et al.
Publicado: (2020) -
Chemotherapy-Induced Sclerosing Cholangitis Caused by Systemic Chemotherapy
por: Kusakabe, Akira, et al.
Publicado: (2019) -
Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer
por: Ikezawa, Kenji, et al.
Publicado: (2021) -
Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules
por: Abe, Yutaro, et al.
Publicado: (2020)